FDA fills four senior leadership roles
Analysis based on 9 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The appointments provide regulatory clarity and stability for pharmaceutical, biotech, and tobacco companies that interact with the FDA, potentially reducing uncertainty around product approvals and policy direction. The new leadership, particularly in drug and vaccine centers, may influence the pace and stringency of reviews, affecting companies with products in those pipelines.
On September 8, 2026, the U.S. Department of Health and Human Services announced the permanent appointment of four senior officials at the United States — Food and Drug Administration, filling roles that had been occupied by acting officials following a series of high-profile departures earlier in the year. Michael Davis was named director of the Center for Drug Evaluation and Research, Karim Mikhail as director of the vaccines center, Bret Koplow as director of the Center for Tobacco Products, and Jared Seehafer in a newly created position overseeing artificial intelligence and technology. The appointments aim to bring stability to the agency after months of controversy and leadership turnover, including the departures of former FDA Commissioner Marty Makary, vaccine center director Vinay Prasad, and drug center director Tracy Beth Høeg. The new leaders will oversee significant policy areas, including the review of psychedelic drugs, vaccine approval processes, and tobacco product regulation.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard